Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment

Although gemcitabine monotherapy is the standard treatment for advanced pancreatic cancer, patient outcome varies significantly, and a considerable number do not benefit adequately. We therefore searched for new biomarkers predictive of overall patient survival. Using LC-MS, we compared the base-lin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular & cellular proteomics 2010-04, Vol.9 (4), p.695-704
Hauptverfasser:	Matsubara, Junichi, Ono, Masaya, Honda, Kazufumi, Negishi, Ayako, Ueno, Hideki, Okusaka, Takuji, Furuse, Junji, Furuta, Koh, Sugiyama, Emiko, Saito, Yoshiro, Kaniwa, Nahoko, Sawada, Junichi, Shoji, Ayako, Sakuma, Tomohiro, Chiba, Tsutomu, Saijo, Nagahiro, Hirohashi, Setsuo, Yamada, Tesshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents - therapeutic use Biomarkers, Tumor - isolation & purification Biomarkers, Tumor - metabolism Calibration Carcinoma, Pancreatic Ductal - diagnosis Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - mortality Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Early Detection of Cancer - methods Early Detection of Cancer - standards Female Gemcitabine Humans Male Middle Aged Neoplasm Proteins - analysis Neoplasm Proteins - isolation & purification Neoplasm Proteins - metabolism Pancreatic Neoplasms - diagnosis Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - mortality Prognosis Retrospective Studies Survival Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!